Ruxolitinib's mode of action may entail an interference with interferon-gamma signaling and Janus kinases, as evidenced by the quick improvements seen in individuals with vitiligo and alopecia areata who received treatment for the conditions. The gene discussed is IFNG; the disease is vitiligo.